These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12089482

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
    Avril N, Adler LP.
    Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
    [Abstract] [Full Text] [Related]

  • 3. Fluorodeoxyglucose-PET in the management of breast cancer.
    Kumar R, Alavi A.
    Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.
    Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, Oh SK, Choe KJ, Noh DY.
    World J Surg; 2001 Jul; 25(7):829-34. PubMed ID: 11572019
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [The value of F-18 fluorodeoxyglucose in positron emission tomography diagnosis of breast carcinoma].
    Langsteger W, Jörg L, Tausch C, Heinisch M, Wieser B, Rechberger E, Panholzer PJ, Sega W, Aufschnaiter M.
    Wien Med Wochenschr; 2002 Jul; 152(11-12):255-8. PubMed ID: 12138651
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS, Chen TC, Yen RF, Shen YY, Changlai SP, Kao A.
    Anticancer Res; 2001 Jul; 21(4B):2957-61. PubMed ID: 11712793
    [Abstract] [Full Text] [Related]

  • 10. Current and future uses of positron emission tomography in breast cancer imaging.
    Eubank WB, Mankoff DA.
    Semin Nucl Med; 2004 Jul; 34(3):224-40. PubMed ID: 15202103
    [Abstract] [Full Text] [Related]

  • 11. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer--Taiwanese experiences.
    Lin WY, Tsai SC, Cheng KY, Yen RF, Kao CH.
    Cancer Invest; 2002 Jul; 20(5-6):725-9. PubMed ID: 12197228
    [Abstract] [Full Text] [Related]

  • 12. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, Cortese AA, Hayes CE, Moe RE.
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, Bombardieri E, Cascinelli N.
    J Natl Cancer Inst; 2001 Apr 18; 93(8):630-5. PubMed ID: 11309439
    [Abstract] [Full Text] [Related]

  • 15. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N, Dose J, Jänicke F, Ziegler S, Römer W, Weber W, Herz M, Nathrath W, Graeff H, Schwaiger M.
    J Natl Cancer Inst; 1996 Sep 04; 88(17):1204-9. PubMed ID: 8780629
    [Abstract] [Full Text] [Related]

  • 16. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar 04; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 17. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun 04; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 18. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E.
    Eur J Nucl Med Mol Imaging; 2004 Jun 04; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [Abstract] [Full Text] [Related]

  • 19. [Indications for the use of PET or PET/CT in patients with breast cancer].
    Bernsdorf M, Graff J.
    Ugeskr Laeger; 2011 Oct 17; 173(42):2638-41. PubMed ID: 22027163
    [Abstract] [Full Text] [Related]

  • 20. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.
    Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW.
    J Cancer Res Clin Oncol; 2003 Mar 17; 129(3):147-53. PubMed ID: 12712329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.